| | | | | | | | Capable of targeting previously 'undruggable' proteins for complex disease treatments like cancer, molecular glue degraders are generating a rising interest from key pharma players. |
|
|
|
| |
| | |
|
|
| | | | | In a phase 3 trial, Columvi plus chemo improved survival rates for patients with relapsed or refractory diffuse large B-cell lymphoma. |
|
|
| Already approved in PNH, Fabhalta heads towards another indication with a phase 3 win in rare kidney disease. |
|
|
|
| |
| | |
|
|
| | | | Sponsored | | mRNA-LNP manufacturing is fraught with obstacles, resulting in higher program risk, inflated costs, and delayed market release. With the right knowledge, companies can overcome the challenges to de-risk & optimize the path to manufacturing success. |
|
|
|
| |
| | |
|
|
| | |
|
| | |
|
